About VLP Therapeutics

vlptherapeutics.com

VLP Therapeutics Japan, FUJIFILM sign contract manufacturing agreement for COVID-19 vaccine

2020-10-01T08:04:54-04:002020.10.01|

October 1, 2020 — VLP Therapeutics Japan, LLC (VLPTJ) announced on today that VLPTJ signed a contract manufacturing agreement with FUJIFILM Corporation (FUJIFILM) for a novel coronavirus (COVID-19) vaccine formulation developed by VLPTJ. This self-amplifying (replicon) RNA vaccine employs a platform technology proprietary to VLP Therapeutics, LLC, the US-based wholly owning parent company of VLPTJ.

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute

2018-05-10T22:27:03-04:002017.10.06|

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines announced today the receipt of a Phase I

Journal of Virology – 27 September 2017

2017-10-09T00:57:38-04:002017.09.27|

“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata   http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017-07-22T06:05:57-04:002017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer. Mr. Licht comes to VLP Therapeutics with nearly 20 years of business development and strategy experience

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017-10-09T00:57:52-04:002017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P. Zavala, Michael G. Rossmann, Sachiko Kuno,a Ryuji Ueno, Wataru Akahata http://cvi.asm.org/content/24/7/e00090-17.full.pdf+html